Abstract
Background/aim
COVID-19 has become the biggest health problem of this century. It has been hypothesized that immunity against hepatitis A virus (HAV) may provide protection from COVID- 19.
Materials and methods
As of 10June 2020, the infection had spread to 213 countries, with 7.3 million people infected and 413,733 dead. This data was combined with the World Health Organization susceptibility classification on the worldwide prevalence of HAV, and the relationship between HAV susceptibility and COVID-19 mortality were analyzed.
Results
When the data from 213 countries were analyzed, it was found that there was a significant increasing trend in COVID-19 mortality rates by HAV susceptibility (P <0.001). Using a cut-off of 200/million population, the mortality risk associated with living in a more susceptible country (medium/high) was 27.8 times higher (95% CI for OR: 3.6–213.2)
Conclusion
The results of this study showed that, despite confounding factors in different countries, hepatitis A susceptibility of the population may have been correlated with COVID-19 mortality. This observation needs to be confirmed by further studies.
Keywords: Hepatitis A, COVID-19, vaccine, mortality
To the Editor,
The COVID-19 pandemic has become the biggest health problem of this century. Several factors have caused the impact of the disease to vary among countries. It had been previously hypothesized that immunity against hepatitis A virus (HAV) may provide protection from COVID-19 [1], and herein, it was aimed to support this hypothesis with data.
As of 10 June 2020, the infection had spread to 213 countries, with 7.3 million people infected and 413,733 dead Worldometer (2020).Coronavirus COVID-19 Statistics [online]. Website https://www.worldometers.info/coronavirus/ [accessed 10 June 2020].. This publicly available data was combined with the World Health Organization susceptibility classification published in 2009 on the worldwide prevalence of hepatitis A [2]. Figures 1 and 2 show the significant increasing trend in COVID-19 mortality rates by HAV susceptibility (P <0.001, Jonckheere–Terpstra test). Moreover, using a cut-off of 200/million population,the mortality risk associated with living in a more susceptible country (medium/high) was 27.8 times higher (95%CI for OR: 3.6–213.2) (Table).
Table.
Mortality rate | Mortality rate | |||||||
---|---|---|---|---|---|---|---|---|
<200 per million | ≥200 per million | OR (95% CI) | <7/million | ≥7/million | OR (95%CI) | All countries | ||
All countries(N = 213) | Very low, low, or low-medium | 121 | 1 | Reference | 80 | 42 | Reference | 122 |
Medium or high | 74 | 17 | 27.8 (3.6–213.2) | 26 | 65 | 4.76 (2.6–8.6) | 91 | |
Total | 195 | 18 | 106 | 107 | 213 | |||
Countries with >1 million population | Very low, low, or low-medium | 106 | 1 | Reference | 70 | 37 | Reference | 107 |
Medium or high | 38 | 11 | 30.7 (3.8–245.7) | 8 | 41 | 9.69 (4.1–22.8) | 49 | |
Total | 144 | 12 | 78 | 78 | 156 | |||
Countries with >5 million population | Very low, low, or low-medium | 85 | 1 | Reference | 58 | 28 | Reference | 86 |
Medium or high | 26 | 10 | 32.6 (4.00–267.5) | 6 | 30 | 10.4 (3.9–27.8) | 36 | |
Total | 111 | 11 | 64 | 58 | 122 | |||
Countries with >5000 tests/1 million population | Very low, low, or low-medium | 50 | 1 | Reference | 26 | 25 | Reference | 51 |
Medium or high | 61 | 17 | 13.9 (1.8–108.4) | 18 | 60 | 3.5 (1.6–7.4) | 78 | |
Total | 111 | 18 | 44 | 85 | 129 |
Association of high HAV susceptibility and high COVID-19 mortality holds in different subgroups. Two cut-offs were used: 7 (the median) and 200 (derived from the receiver operator curve analysis). OR: odds ratio showing risk in medium, high group when compared to the very low, low, low-medium group.
Several known facts supported the hypothesis. Although children constitute a very significant risk group for several respiratory viruses, they seemed to have been spared from COVID-19. The immunity of children against HAV (a virus with similar taxonomy to coronaviruses), acquired either by vaccination in developed countries or by infection in underdeveloped countries, may have contributed to this protection. The loss of immunity to HAV as the result of aging may have led to an increased COVID-19 morbidity in the elderly.
The Diamond Princess ship experience also supported this theory. Of the 3711 passengers and crew members, 58% were over the age of 60. In total, 712 of the passengers were infected and 13 died (1.8% fatality).The asymptomatic infection rate was 57% in elderly individuals over the age of 60 [3]. Thus far, the reason for this extremely low fatality and unusually high asymptomatic infection rate has not been explained. The Centers for Disease Control and Prevention recommendation that all susceptible people traveling for any purpose, frequency, or duration to countries with high or intermediate HAV endemicity should be vaccinated before departure, which all notable cruise lines to Asia comply with, may have been one explanation [4].
We are aware that this ecological analysis is far from pointing to a causal relationship. However, given the simplicity and the very low risk/benefit ratio of the preventive measures, it is far from being negligible.
We are proceeding with detailed analyses, to try and find confounders that may have led to this association, but with this letter, we are urging the medical community to help in challenging this hypothesis. If confirmed, the consequences of this simple discovery will be enormous.
Informed consent
As this was an evaluation of publicly available open access data, informed consent was not required.
Acknowledgment/Disclaimers/Conflict of interest
There was no funding provided for this work. The authors declare that there are no conflicts of interest.
References
- Sarialioglu F Belen Apak FB Haberal M. Can hepatitis A vaccine provide protection against. COVID-19? Experimental and Clinical Transplantation . 2020;18:141–143. doi: 10.6002/ect.2020.0109. [DOI] [PubMed] [Google Scholar]
- The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Report number: WHO/IVB/10 . 2009.
- Sakurai A Sasaki T Kato S Hayashi M Tsuzuki SI Natural history of asymptomatic SARS-CoV-2 infection. The New England Journal of Medicine . 2020;383:885–886. doi: 10.1056/NEJMc2013020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Travel related infectious diseases- hepatitis A. Centers for Disease Control and Prevention. CDC Yellow Book . 2020.